Boost For Daiichi's Oncology Ambitions As AZ Agrees Huge $6.9bn Deal For Lead ADC Asset

 
• By Ian Haydock

AstraZeneca is paying $1.35bn upfront for global rights to a flagship Daiichi Sankyo oncology asset, in a deal potentially worth up to $6.9bn set to give a huge boost to the Japanese firm's ambitions in the sector.

Dividing breast cancer cell
AZ Strikes Major Deal For Daiichi Cancer ADC • Source: Shutterstock

More from Anticancer

More from Therapy Areas